Literature DB >> 14554157

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.

Dante J Marciani1.   

Abstract

Inactivated vaccines require adjuvants to stimulate an immune response. The choice of adjuvant or immune enhancer determines whether the immune response is effective, ineffective or damaging. Accordingly, there is a need for new adjuvants that stimulate the appropriate immunity, for example, T cell immunity for intracellular pathogens and cancer vaccines. In several adjuvants, the identification of chemical groups that interact with specific cell toll-like receptors (innate immunity) or receptors for co-stimulatory ligands (adaptive immunity), has enabled the establishment of structure-function relationships that are useful in the design of new adjuvants. Because of the crucial immunomodulating role of adjuvants, sub-unit vaccine development will remain dependent on new adjuvants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14554157     DOI: 10.1016/s1359-6446(03)02864-2

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  66 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

Review 2.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

3.  A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.

Authors:  David C Jackson; Yuk Fai Lau; Thuy Le; Andreas Suhrbier; Georgia Deliyannis; Christina Cheers; Corey Smith; Weiguang Zeng; Lorena E Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

4.  TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B.

Authors:  Dalia E Gaddis; Suzanne M Michalek; Jannet Katz
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

Review 5.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

6.  Immunization with recombinant Pb27 protein reduces the levels of pulmonary fibrosis caused by the inflammatory response against Paracoccidioides brasiliensis.

Authors:  Elis Araujo Morais; Estefânia Mara do Nascimento Martins; Jankerle Neves Boelone; Dawidson Assis Gomes; Alfredo Miranda Goes
Journal:  Mycopathologia       Date:  2014-12-09       Impact factor: 2.574

Review 7.  Augmentation of antibody responses by retinoic acid and costimulatory molecules.

Authors:  A Catharine Ross; Qiuyan Chen; Yifan Ma
Journal:  Semin Immunol       Date:  2008-09-25       Impact factor: 11.130

8.  Design and synthesis of potent Quillaja saponin vaccine adjuvants.

Authors:  Michelle M Adams; Payal Damani; Nicholas R Perl; Annie Won; Feng Hong; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  J Am Chem Soc       Date:  2010-02-17       Impact factor: 15.419

9.  Towards identification of the mechanisms of action of parasite-derived peptide GK1 on the immunogenicity of an influenza vaccine.

Authors:  René Segura-Velázquez; Gladis Fragoso; Edda Sciutto; Adelaida Sarukhan
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

10.  Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.

Authors:  Dirlei Nico; Carla Claser; Gulnara P Borja-Cabrera; Luiz R Travassos; Marcos Palatnik; Irene da Silva Soares; Mauricio Martins Rodrigues; Clarisa B Palatnik-de-Sousa
Journal:  PLoS Negl Trop Dis       Date:  2010-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.